Jocelyn Chapman

Jocelyn Chapman

Auto-generated profile, based on publicly available information

Jocelyn Chapman

University of California, San Francisco 2 Helen Diller Family Comprehensive Cancer Center San Francisco, California

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Gynecologic Oncology
Verified
Journal Article
Open access
WPWilliam E. Pierson
William E. Pierson
PPPamela N. Peters
Pamela N. Peters
MCMatthew T. Chang
Matthew T. Chang
LCLee-May Chen
Lee-May Chen
DQDavid A. Quigley
David A. Quigley
JCJocelyn S. Chapman
Jocelyn S. Chapman
Endometrioid ovarian carcinoma (EOVC) is an uncommon subtype of epithelial ovarian carcinoma and its molecular characteristics have been incompletely described. Prior sequencing investigations have been limited to targeted gene panels. We performed whole-exome sequencing to build an unbiased genetic profile of molecular alterations in endometrioid ovarian tumors with a goal to better understand this disease in the context of epithelial ovarian cancer and endometrioid uterine cancers. Whole-exome sequencing was performed on EOVC samples (n = 26) and matched normals (n = 15). Gene mutations, mutational signatures and copy number variations (CNVs) informed a multi-dimensional regression classifier allowing for comparison to endometrial carcinoma (UCEC) and high grade serous ovarian carcinoma (HGSC). EOVC has a distinct and heterogeneous genomic profile. Identified significantly mutated genes in EOVC (PTEN, CTNNB1, PIK3CA, KMT2D, KMT2B, PIK3R1, ARID1A and TP53) occurred at similar frequencies in UCEC. Hypermutation, resulting from both mismatch repair deficiency (MMRd) and POLE mutation, was observed in EOVC at a frequency similar to UCEC. Like UCEC, a subset of EOVC cases closely resembled HGSC, harboring TP53 mutations, homologous recombination deficiency (HRd) mutation signatures and widespread CNVs. A machine-learning classifier confirmed the heterogeneous composition of EOVC. Potential therapeutic targets were identified in 62% of EOVC cases. We validated our findings in an orthogonal clinical sequencing registry of EOVC cases. We identified that EOVC are a molecularly heterogeneous group of epithelial ovarian cancers with distinct mutational signatures. In an age of precision oncology, there is a pressing need to understand the unique molecular drivers in uncommon histologic subtypes to facilitate genomically driven oncologic treatments.

4 March 2021 in Science Immunology
Verified
Journal Article
Closed access
PDF file
RSRobert Seed
Robert Seed
KKKenji Kobayashi
Kenji Kobayashi
SISaburo Ito
Saburo Ito
NTNaoki Takasaka
Naoki Takasaka
ACAnthony Cormier
Anthony Cormier
SNStephen L. Nishimura
Stephen L. Nishimura
Tumor cells expressing integrin αvβ8 activated latent TGF-β on T cells, inducing T reg enrichment and tumor immunosuppression.

11 January 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
IGInes Guix
Ines Guix
QLQi Liu
Qi Liu
MPMiquel Angel Pujana
Miquel Angel Pujana
PHPatrick Ha
Patrick Ha
JPJosep Piulats
Josep Piulats
MBMary Helen Barcellos-Hoff
Mary Helen Barcellos-Hoff
Purpose: Loss of TGFβ signaling increases error-prone alternative end-joining (alt-EJ) DNA repair. We previously translated this mechanistic relationship as TGFβ and alt-EJ gene expression signatures, which we showed are anticorrelated across cancer types. A score representing anticorrelation, βAlt, predicts patient outcome in response to genotoxic therapy. Here we sought to verify this biology in live specimens and additional datasets. Experimental Design: Human head and neck squamous carcinoma (HNSC) explants were treated in vitro to test whether the signatures report TGFβ signaling, indicated by SMAD2 phosphorylation, and unrepaired DNA damage, indicated by persistent 53BP1 foci after irradiation or olaparib. A custom NanoString assay was implemented to analyze the signatures’ expression in explants. Each signature gene was then weighted by its association with functional responses to define a modified score, βAltw, that was retested for association with response to genotoxic therapies in independent datasets. Results: Most genes in each signature were positively correlated with the expected biological response in tumor explants. Anticorrelation of TGFβ and alt-EJ signatures measured by NanoString was confirmed in explants. βAltw was significantly (P < 0.001) better than βAlt in predicting overall survival in response to genotoxic therapy in The Cancer Genome Atlas (TCGA) pancancer patients and in independent HNSC and ovarian cancer patient datasets. Conclusions: Association of the TGFβ and alt-EJ signatures with their biological response validates TGFβ competency as a key mediator of DNA repair that can be readily assayed by gene expression. The predictive value of βAltw supports its development to assist in clinical decision making.

1 January 2017 in Current Problems in Cancer
Verified
Journal Article
Closed access
ERErika Roddy
Erika Roddy
JCJocelyn Chapman
Jocelyn Chapman

1 December 2016 in Clinical Breast Cancer
Verified
Journal Article
Closed access
JCJocelyn S. Chapman
Jocelyn S. Chapman
ERErika Roddy
Erika Roddy
APAnna Panighetti
Anna Panighetti
SHShelley Hwang
Shelley Hwang
BCBeth Crawford
Beth Crawford
LCLee-May Chen
Lee-May Chen

1 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
TLTianyi Liu
Tianyi Liu
MZMeng Zhang
Meng Zhang
TFTatyanah Farsh
Tatyanah Farsh
HLHaolong Li
Haolong Li
AKAudrey Kishishita
Audrey Kishishita
Carl DeSelmCarl DeSelm
Carl DeSelm
Macrophages infiltrate solid tumors and either support survival or induce cancer cell death through phagocytosis or cytotoxicity. To uncover regulators of macrophage cytotoxicity towards cancer cells, we perform two co-culture CRISPR screens using CAR-macrophages targeting different tumor associated antigens. Both identify ATG9A as an important regulator of this cytotoxic activity. In vitro and in vivo, ATG9A depletion in cancer cells sensitizes them to macrophage-mediated killing. Proteomic and lipidomic analyses reveal that ATG9A deficiency impairs the cancer cell response to macrophage-induced plasma membrane damage through defective lysosomal exocytosis, reduced ceramide production, and disrupted caveolar endocytosis. Depleting non-cytotoxic macrophages using CSF1R inhibition while preventing ATG9A-mediated tumor membrane repair enhances the anti-tumor activity of therapeutic antibodies in mice. Thus, macrophage cytotoxicity plays an important role in tumor elimination during antibody or CAR-macrophage treatment, and inhibiting tumor membrane repair via ATG9A, particularly in combination with cytotoxic macrophage enrichment through CSF1R inhibition, improves tumor-targeting macrophage efficacy.